

1. Sales January to September 2008 and 2007

	2008	2007	% change	
	CHF m	CHF m	In CHF	In local currencies
January – September				
Pharmaceuticals Division	26,193	27,124	-3	+4
Roche Pharmaceuticals	16,423	16,792	-2	+3
Genentech	7,536	7,850	-4	+11
Chugai	2,234	2,482	-10	-8
Diagnostics Division	7,112	6,823	+4	+11
Roche Group	33,305	33,947	-2	+6

2. Sales January to September 2008 and 2007 excluding Pandemic Tamiflu*

	2008	2007	% change	
	CHF m	CHF m	In CHF	In local currencies
January – September				
Pharmaceuticals Division	26,062	25,726	+1	+10
Roche Pharmaceuticals	16,294	15,668	+4	+10
Genentech	7,536	7,850	-4	+11
Chugai	2,232	2,208	+1	+3
Diagnostics Division	7,112	6,823	+4	+11
Roche Group	33,174	32,549	+2	+10

* excluding government & corporate pandemic Tamiflu sales; including seasonal Tamiflu sales

3. Quarterly local sales growth by Division in 2007 and 2008

	Q4 2007 vs. Q4 2006	Q1 2008 vs. Q1 2007	Q2 2008 vs. Q2 2007	Q3 2008 vs. Q3 2007
Pharmaceuticals Division	+5	+1	+5	+8
Roche Pharmaceuticals	+7	+1	+3	+6
Genentech	+6	+9	+9	+14
Chugai	-8	-23	+2	-1
Diagnostics Division	+8	+9	+13	+11
Roche Group	+6	+2	+7	+9

4. Quarterly local sales growth by Division in 2007 and 2008 excluding Pandemic Tamiflu*

	Q4 2007 vs. Q4 2006	Q1 2008 vs. Q1 2007	Q2 2008 vs. Q2 2007	Q3 2008 vs. Q3 2007
Pharmaceuticals Division	+11	+9	+10	+10
Roche Pharmaceuticals	+14	+11	+11	+8
Genentech	+6	+9	+9	+14
Chugai	+4	-2	+2	+10
Diagnostics Division	+8	+9	+13	+11
Roche Group	+10	+9	+10	+10

* excluding government & corporate pandemic Tamiflu sales; including seasonal Tamiflu sales

5. Quarterly sales by Division in 2007 and 2008

CHF millions	Q3 2007	Q4 2007	Q1 2008	Q2 2008	Q3 2008
Pharmaceuticals Division	8,856	9,659	8,568	8,689	8,936
Roche Pharmaceuticals	5,425	6,178	5,498	5,440	5,485
Genentech	2,623	2,564	2,399	2,468	2,669
Chugai	808	917	671	781	782
Diagnostics Division	2,264	2,527	2,287	2,460	2,365
Roche Group	11,120	12,186	10,855	11,149	11,301

6. Quarterly sales by Division in 2007 and 2008 excluding Pandemic Tamiflu*

CHF millions	Q3 2007	Q4 2007	Q1 2008	Q2 2008	Q3 2008
Pharmaceuticals Division	8,664	9,201	8,523	8,639	8,900
Roche Pharmaceuticals	5,314	5,736	5,455	5,390	5,449
Genentech	2,623	2,564	2,399	2,468	2,669
Chugai	727	901	669	781	782
Diagnostics Division	2,264	2,527	2,287	2,460	2,365
Roche Group	10,928	11,728	10,810	11,099	11,265

* excluding government & corporate pandemic Tamiflu sales; including seasonal Tamiflu sales

7. Top 20 Pharmaceuticals Division product sales¹ and local growth² in YTD September 2008: US, Japan and Europe/Rest of World

	Total		US		Japan		Europe/RoW	
	CHF m	%	CHF m	%	CHF m	%	CHF m	%
MabThera/Rituxan	4,339	16%	2,113	14%	146	11%	2,080	20%
Herceptin	3,769	12%	1,106	9%	162	38%	2,501	13%
Avastin	3,702	37%	2,067	15%	128	878%	1,507	74%
CellCept	1,523	14%	705	16%	28	16%	790	11%
NeoRecormon/Epogin	1,319	-14%	-	-	328	-19%	991	-12%
Pegasys	1,190	6%	275	11%	67	62%	848	2%
Tarceva	885	24%	359	12%	31	-	495	28%
Xeloda	880	14%	297	9%	33	71%	550	14%
Bonviva/Boniva	775	41%	467	33%	-	-	308	59%
Lucentis	686	4%	686	4%	-	-	-	-
Tamiflu	428	-69%	360	-27%	17	-95%	51	-92%
Valcyte/Cymevene	404	11%	182	8%	-	-	222	14%
Xolair	404	9%	404	9%	-	-	-	-
Xenical	390	-14%	35	-39%	-	-	355	-10%
Pulmozyme	357	11%	195	12%	-	-	162	8%
Nutropin	301	-3%	292	-3%	-	-	9	-8%
Neutrogen	290	1%	-	-	290	1%	-	-
Rocephin	252	-11%	4	-73%	42	2%	206	-9%
Activase/TNKase	245	-5%	212	-7%	-	-	33	9%
Madopar	231	4%	-	-	14	5%	217	4%

¹ Roche Pharmaceuticals, Genentech and Chugai combined

² versus YTD September 2007

8. Top 20 Pharmaceuticals Division quarterly local product sales growth¹ in 2007 and 2008

	Q4 2007 vs. Q4 2006	Q1 2008 vs. Q1 2007	Q2 2008 vs. Q2 2007	Q3 2008 vs. Q3 2007
MabThera/Rituxan	12%	17%	16%	15%
Herceptin	14%	11%	12%	14%
Avastin	41%	35%	38%	37%
CellCept	16%	11%	16%	14%
NeoRecormon/Epogin	-15%	-13%	-14%	-15%
Pegasys	14%	-3%	10%	12%
Tarceva	24%	28%	27%	18%
Xeloda	22%	13%	14%	14%
Bonviva/Boniva	63%	56%	47%	26%
Lucentis	-9%	-5%	2%	15%
Tamiflu	-46%	-64%	-86%	-56%
Valcyte/Cymevene	7%	9%	10%	13%
Xolair	2%	6%	7%	12%
Xenical	-17%	-11%	-21%	-9%
Pulmozyme	13%	15%	11%	6%
Nutropin	-8%	-5%	-5%	1%
Neutrogen	14%	1%	1%	0%
Rocephin	-4%	-4%	-13%	-16%
Activase/TNKase	-2%	-3%	-11%	-2%
Madopar	14%	0%	9%	4%

¹ Roche Pharmaceuticals, Genentech and Chugai combined

9. Pharmaceuticals Division quarterly local product sales growth¹ US in 2007 and 2008

	Q4 2007 vs. Q4 2006	Q1 2008 vs. Q1 2007	Q2 2008 vs. Q2 2007	Q3 2008 vs. Q3 2007
MabThera/Rituxan	4%	14%	13%	14%
Herceptin	1%	9%	3%	15%
Avastin	23%	13%	15%	18%
CellCept	17%	14%	15%	20%
NeoRecormon/Epogin	-	-	-	-
Pegasys	-3%	-10%	5%	45%
Tarceva	5%	10%	17%	9%
Xeloda	19%	16%	5%	9%
Bonviva/Boniva	40%	47%	39%	16%
Lucentis	-9%	-5%	2%	15%
Tamiflu	52%	83%	-87%	6%
Valcyte/Cymevene	3%	11%	5%	7%
Xolair	2%	6%	7%	12%
Xenical	-46%	-35%	-46%	-33%
Pulmozyme	10%	10%	14%	13%
Nutropin	-8%	-6%	-4%	1%
Neutrogin	-	-	-	-
Rocephin	-32%	-34%	-85%	-
Activase/TNKase	0%	-6%	-12%	-2%
Madopar	-	-	-	-

¹ Roche Pharmaceuticals and Genentech combined

10. Pharmaceuticals Division quarterly local product sales growth Japan¹ in 2007 and 2008

	Q4 2007 vs. Q4 2006	Q1 2008 vs. Q1 2007	Q2 2008 vs. Q2 2007	Q3 2008 vs. Q3 2007
MabThera/Rituxan	2%	13%	11%	8%
Herceptin	0%	16%	29%	69%
Avastin	-	-	1567%	442%
CellCept	18%	13%	21%	15%
NeoRecormon/Epogin	-22%	-16%	-29%	-9%
Pegasys	53%	98%	53%	49%
Tarceva	-	-	-	-
Xeloda	14%	48%	73%	88%
Bonviva/Boniva	-	-	-	-
Lucentis	-	-	-	-
Tamiflu	-58%	-93%	-78%	-98%
Valcyte/Cymevene	-	-	-	-
Xolair	-	-	-	-
Xenical	-	-	-	-
Pulmozyme	-	-	-	-
Nutropin	-	-	-	-
Neutrogen	14%	1%	1%	0%
Rocephin	-1%	9%	-2%	-1%
Activase/TNKase	-	-	-	-
Madopar	3%	5%	5%	6%

¹ Chugai

11. Pharmaceuticals Division quarterly local product sales growth Europe/Rest of World¹ in 2007 and 2008

	Q4 2007 vs. Q4 2006	Q1 2008 vs. Q1 2007	Q2 2008 vs. Q2 2007	Q3 2008 vs. Q3 2007
MabThera/Rituxan	25%	21%	21%	17%
Herceptin	23%	12%	15%	11%
Avastin	80%	78%	78%	67%
CellCept	14%	8%	16%	9%
NeoRecormon/Epogin	-11%	-13%	-7%	-17%
Pegasys	20%	-4%	9%	1%
Tarceva	47%	40%	28%	17%
Xeloda	25%	11%	18%	14%
Bonviva/Boniva	160%	77%	61%	45%
Lucentis	-	-	-	-
Tamiflu	-92%	-94%	-83%	-93%
Valcyte/Cymevene	11%	8%	16%	19%
Xolair	-	-	-	-
Xenical	-11%	-7%	-17%	-6%
Pulmozyme	17%	22%	8%	-3%
Nutropin	-10%	-1%	-12%	-10%
Neutrogin	-	-	-	-
Rocephin	-3%	-3%	-9%	-13%
Activase/TNKase	-16%	30%	1%	1%
Madopar	15%	0%	9%	4%

¹ Roche Pharmaceuticals

12. Top 20 Pharmaceuticals Division quarterly product sales¹ in 2007 and 2008

CHF millions	Q3 2007	Q4 2007	Q1 2008	Q2 2008	Q3 2008
MabThera/Rituxan	1,380	1,432	1,407	1,460	1,472
Herceptin	1,209	1,261	1,225	1,249	1,295
Avastin	1,062	1,135	1,131	1,220	1,351
CellCept	485	548	487	523	513
NeoRecormon/Epogin	518	510	442	450	427
Pegasys	383	447	369	416	405
Tarceva	271	288	286	301	298
Xeloda	290	312	281	292	307
Bonviva/Boniva	230	283	241	266	268
Lucentis	239	228	215	225	246
Tamiflu	257	512	278	49	101
Valcyte/Cymevene	137	144	125	136	143
Xolair	145	138	125	134	145
Xenical	151	142	136	128	126
Pulmozyme	124	128	117	120	120
Nutropin	118	113	97	98	106
Neutrogen	100	110	95	97	98
Rocephin	95	100	91	85	76
Activase/TNKase	92	88	83	81	81
Madopar	76	83	74	80	77

¹ Roche Pharmaceuticals, Genentech and Chugai combined

13. Pharmaceuticals Division quarterly product sales¹ in US in 2007 and 2008

CHF millions	Q3 2007	Q4 2007	Q1 2008	Q2 2008	Q3 2008
MabThera/Rituxan	718	709	675	706	732
Herceptin	384	375	363	349	394
Avastin	718	693	642	671	754
CellCept	232	290	215	243	247
NeoRecormon/Epogin	-	-	-	-	-
Pegasys	75	111	81	95	99
Tarceva	121	129	119	123	117
Xeloda	114	123	89	97	111
Bonviva/Boniva	150	190	153	159	155
Lucentis	239	228	215	225	246
Tamiflu	98	398	234	30	96
Valcyte/Cymevene	69	73	54	62	66
Xolair	145	138	125	134	145
Xenical	17	13	14	12	9
Pulmozyme	68	67	61	65	69
Nutropin	115	108	94	94	104
Neutrogen	-	-	-	-	-
Rocephin	5	1	3	1	0
Activase/TNKase	80	76	71	71	70
Madopar	-	-	-	-	-

¹ Roche Pharmaceuticals and Genentech combined

14. Pharmaceuticals Division quarterly product sales¹ in Japan in 2007 and 2008

CHF millions	Q3 2007	Q4 2007	Q1 2008	Q2 2008	Q3 2008
MabThera/Rituxan	49	55	43	52	51
Herceptin	39	44	42	56	64
Avastin	10	23	28	43	57
CellCept	9	10	8	11	9
NeoRecormon/Epogin	124	146	103	114	111
Pegasys	17	23	19	22	26
Tarceva	-	2	8	12	11
Xeloda	7	8	8	12	13
Bonviva/Boniva	-	-	-	-	-
Lucentis	-	-	-	-	-
Tamiflu	81	69	16	0	1
Valcyte/Cymevene	-	-	-	-	-
Xolair	-	-	-	-	-
Xenical	-	-	-	-	-
Pulmozyme	-	-	-	-	-
Nutropin	-	-	-	-	-
Neutrogen	100	110	95	97	98
Rocephin	14	16	13	15	14
Activase/TNKase	-	-	-	-	-
Madopar	4	6	4	5	5

¹ Chugai

15. Pharmaceuticals Division quarterly product sales in Europe/Rest of World¹ in 2007 and 2008

CHF millions	Q3 2007	Q4 2007	Q1 2008	Q2 2008	Q3 2008
MabThera/Rituxan	613	668	689	702	689
Herceptin	786	842	820	844	837
Avastin	334	419	461	506	540
CellCept	244	248	264	269	257
NeoRecormon/Epogin	394	364	339	336	316
Pegasys	291	313	269	299	280
Tarceva	150	157	159	166	170
Xeloda	169	181	184	183	183
Bonviva/Boniva	80	93	88	107	113
Lucentis	-	-	-	-	-
Tamiflu	78	45	28	19	4
Valcyte/Cymevene	68	71	71	74	77
Xolair	-	-	-	-	-
Xenical	134	129	122	116	117
Pulmozyme	56	61	56	55	51
Nutropin	3	5	3	4	2
Neutrogen	-	-	-	-	-
Rocephin	76	83	75	69	62
Activase/TNKase	12	12	12	10	11
Madopar	72	77	70	75	72

¹ Roche Pharmaceuticals